CN109498660A - A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis - Google Patents
A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis Download PDFInfo
- Publication number
- CN109498660A CN109498660A CN201811404822.0A CN201811404822A CN109498660A CN 109498660 A CN109498660 A CN 109498660A CN 201811404822 A CN201811404822 A CN 201811404822A CN 109498660 A CN109498660 A CN 109498660A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- atopic dermatitis
- product
- plantarum ccfm8610
- ccfm8610
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 64
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 64
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 64
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 55
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 8
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 8
- 206010014025 Ear swelling Diseases 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 34
- 210000003491 skin Anatomy 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 150000002482 oligosaccharides Polymers 0.000 description 15
- 239000006041 probiotic Substances 0.000 description 14
- 235000018291 probiotics Nutrition 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 10
- 229920001542 oligosaccharide Polymers 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 240000001307 Myosotis scorpioides Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000020167 acidified milk Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000010422 painting Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000556215 Frangula purshiana Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022535 Infectious Skin disease Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
- A23C11/106—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses the applications that one kind can alleviate the lactobacillus plantarum CCFM8610 of atopic dermatitis, belong to microorganisms technical field and pharmaceutical technology field.Present invention discover that lactobacillus plantarum CCFM8610 has the function of alleviating atopic dermatitis, it is embodied in: (1) significantly improves the ear swelling degree of atopic dermatitis mouse；(2) the dermatopathology symptom of atopic dermatitis mouse is significantly improved；(3) the SCORAD index of slight atopic dermatitis patients is significantly reduced；(4) the DLQI scoring of slight atopic dermatitis patients is significantly improved, therefore, lactobacillus plantarum CCFM8610 has huge application prospect in the product of preparation prevention and/or treatment atopic dermatitis.
Description
Technical field
The present invention relates to the applications that one kind can alleviate the lactobacillus plantarum CCFM8610 of atopic dermatitis, belong to microorganism
Technical field and pharmaceutical technology field.
Background technique
Atopic dermatitis (Atopic Dermatitis, AD) is a kind of chronic, recurrent, inflammatory skin disease, disease hair
When often with violent itch, while with the skin disease of other anaphylactias.Meanwhile AD is a kind of common non-infectious
Skin disease, global most countries influence up to 20% children and 2-8% adult (Wollenberg A etc.,
2018), clinical manifestations diversification, according to its occur, development and characteristic distributions, can be divided into infancy, childhood, blueness
Juvenile and adulthood three phases, wherein most of AD patients occur in infancy, and serious patient even may persist to adult
Phase is one of global public health problem since its repeatability seriously affects the quality of life of patient.
The factor relations such as the morbidity of AD and h and E are close, but really cause the pathogenesis of AD unclear.One
As be considered on the basis of inherent cause, patient contact anaphylactogen forms cutaneous immunisation abnormal response and inflammation, cause fash and
Itch.There are multiple abnormal immunes to react link during the occurrence and development of AD, and such as: Langerhans cell and skin dendron are thin
Born of the same parents to the offering of allergen, the abnormal immune reaction based on Th2, regulatory T cells dysfunction, IgE are excessively generated and acidophilus
Property granulocyte increase etc..
At this stage, there is no the therapeutic agents with clear curative effect for AD therefore presently mainly to pass through external application
Drug such as glucocorticoid medicine, Calcineurin inhibitors, external application anti-microbial agents, antihistamine and anti-inflammatory
Medium drug, immunosuppressor etc. alleviate the symptom of AD.
But there are biggish adverse reactions for said medicine, also, most of patients has misgivings to hormone medicine, this
Great difficulty all is brought to AD treatment a bit, meanwhile, also great puzzlement is brought to the life of patient.
Therefore, there is still a need for a kind of drug or therapeutic modality, will not both bring side effect, while also can be used in patient
Development to antianaphylactic breaking-out and scytitis, and can be applied to patient of all categories.
In recent years, a large amount of studies have shown that enteric microorganism and immune-related allergic skin diseases relationship are very close, intestines
Road microorganism may play an important role in anaphylactic disease pathogenic process.For example, Shreiner etc. (2005) proposes that enteron aisle is micro-
Biology causes the hypothesis of anaphylactia, it is believed that and enteric microorganism plays a significant role reaching maturity for host immune system,
It is acted on especially in terms of maintaining mucosa-immune tolerance significant；In addition, transforming growth factor-β (the TGF- that enteric microorganism generates
Generation β), inhibit Th2 induction allergic inflammation and induction oral tolerance in terms of play an important role, can improve Th1 and
Balance between Th2, thus Reduce allergy disease；Also, studies have found that enteron aisle in adult atopic dermatitis patients excrement
Microbial status has correlation with coincident with severity degree of condition, and the diversity of Intestinal Mucosal Injury in Patients Undergoing microorganism reduces, Bifidobacterium
(Bifidobacterium) it is significantly dropped compared with the control group of health with the relative abundance of Bacillus acidi lactici (Lactobacillus)
Low (Watanabe S etc., 2003；B etc., 2010；B etc., 2001), to speculate that enteric microorganism can
It can be had an impact during the occurrence and development of atopic dermatitis.
Therefore, it perhaps can start with from enteric microorganism, attempt the novel drugs or new method that find treatment AD, it is existing to overcome
The defect of therapeutic agent and treatment method adverse reaction obviously etc..
Summary of the invention
Present invention discover that lactobacillus plantarum CCFM8610 has the function of alleviating atopic dermatitis, it is embodied in: (1) shows
Write the ear swelling degree for improving atopic dermatitis mouse；(2) the dermatopathology symptom of atopic dermatitis mouse is significantly improved；
(3) the SCORAD index of slight atopic dermatitis patients is significantly reduced；(4) DLQI of slight atopic dermatitis patients is significantly improved
Scoring, therefore, lactobacillus plantarum CCFM8610 have huge answer in the product of preparation prevention and/or treatment atopic dermatitis
Use prospect.
Technical scheme is as follows:
The present invention provides lactobacillus plantarum CCFM8610 in the product of preparation prevention and/or treatment atopic dermatitis
Using.
The lactobacillus plantarum CCFM8610 is recorded in the patent application text of Publication No. CN102827796A, in
On May 3rd, 2012 is in Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 Institute of Microorganism, Academia Sinica China Microbiological bacterium
Kind preservation administration committee common micro-organisms center preservation, deposit number are CGMCC No.6077.
In one embodiment of the invention, in the product, the viable count of lactobacillus plantarum CCFM8610 is not low
In 1 × 106CFU/mL。
In one embodiment of the present invention, the product includes food, drug or health care product.
In one embodiment of the present invention, the drug contains lactobacillus plantarum CCFM8610, pharmaceutical carrier and/or medicine
Use auxiliary material.
In one embodiment of the present invention, the food includes to use the leavening containing lactobacillus plantarum CCFM8610
Produce obtained dairy products, bean product or fruit and vegetable product；Or the food includes the solid containing lactobacillus plantarum CCFM8610
Beverage.
The present invention provides a kind of for preventing and/or treating the product of atopic dermatitis, and the product contains plant cream
Bacillus CCFM8610.
In one embodiment of the present invention, in the product, the viable count of lactobacillus plantarum CCFM8610 is not less than 1
×106CFU/mL。
In one embodiment of the present invention, the product includes food, drug or health care product.
In one embodiment of the present invention, the drug contains lactobacillus plantarum CCFM8610, pharmaceutical carrier and/or medicine
Use auxiliary material.
In one embodiment of the present invention, the food includes to use the leavening containing lactobacillus plantarum CCFM8610
Produce obtained dairy products, bean product or fruit and vegetable product；Or the food includes the solid containing lactobacillus plantarum CCFM8610
Beverage.
In one embodiment of the invention, the preparation method of the leavening is to press lactobacillus plantarum CCFM8610
It is inoculated into culture medium according to the inoculum concentration for accounting for culture medium gross mass 2~4%, cultivates 18h at 37 DEG C, obtain culture solution；It will training
Nutrient solution centrifugation, obtains thallus；It is resuspended after thallus is cleaned 2~4 times with the phosphate buffer that pH is 7.2 with protective agent dense to bacterium
Degree is not less than 1 × 1010CFU/ml obtains bacteria suspension；Suspension is placed after 60min carries out preculture at 37 DEG C and uses freeze-drying
Method freeze-drying, obtains leavening.
In one embodiment of the invention, the culture medium includes the water for accounting for culture medium gross mass 87.7%, 10%
Enzyme hydrolysis skimmed milk, 0.5% glucose, 1.5% tryptone and 0.3% yeast extract dissolution.
In one embodiment of the invention, the pH of the culture medium is 6.8.
In one embodiment of the invention, the protective agent include the skimmed milk power of 100g/L, 30mL/L glycerol,
The L-sodium of the maltodextrin of 100g/L, the trehalose of 150g/L and 10g/L.
The utility model has the advantages that
Present invention discover that lactobacillus plantarum CCFM8610 has the function of alleviating atopic dermatitis, it is embodied in: (1) shows
Write the ear swelling degree for improving atopic dermatitis mouse；(2) the dermatopathology symptom of atopic dermatitis mouse is significantly improved；
(3) the SCORAD index of slight atopic dermatitis patients is significantly reduced；(4) DLQI of slight atopic dermatitis patients is significantly improved
Scoring, therefore, lactobacillus plantarum CCFM8610 are special in preparation prevention and/or treatment atopic dermatitis or even prevention and/or treatment
In the product of answering property dermatitis, there is huge application prospect.
Detailed description of the invention
Fig. 1: different groups reduce the Contrast on effect of atopic dermatitis mouse ear thickness；
Fig. 2: different groups alleviate the Contrast on effect of atopic dermatitis mouse skin inflammation；
Fig. 3: the SCORAD index clinical test process of atopic dermatitis patients；
Fig. 4: different groups reduce the Contrast on effect of slight atopic dermatitis patients SCORAD index；
Fig. 5: different groups reduce the Contrast on effect of slight atopic dermatitis patients DLQI scoring.
Specific embodiment
The present invention will be further elaborated combined with specific embodiments below.
Enzyme hydrolysis skimmed milk, glucose, tryptone and yeast extract involved in following embodiments are purchased from Shanghai medicine
Group Plc.
Detection method involved in following embodiments is as follows:
The detection method of viable count: national standard " GB 4789.35-2016 national food safety standard Food Microbiology is used
Detect lactic acid bacteria detection ".
Embodiment 1: influence of the lactobacillus plantarum CCFM8610 to atopic dermatitis mouse ear thickness
Weight is taken in the Healthy female C57BL/6 mouse 50 of 18-20g, is randomly divided into 5 groups, every group 10,5 groups of difference
Are as follows: blank group (Control), the model group that 2,4-dinitrofluorobenzene (2,4-dinitrofluorobenzene, DNFB) is administered
(Model), the CCFM8610 group that lactobacillus plantarum CCFM8610 is administered, is given at the Bb-12 group that animal bifidobacteria Bb-12 is administered
The LGG group of cascara buckthorn sugar Lactobacillus rhamnosus GG, wherein CCFM8610 group, Bb-12 group, LGG group are treatment group.
Model group is put in the DNFB solution painting that experiment the totally two weeks: 1st day is 0.5% with 50 μ L concentration on the skin and treatment group mouse is right
Skin lesion sensitization and excitation are carried out at ear, are applied with the DNFB solution that 20 μ L concentration are 0.2% within the 5th day, the 8th day, the 11st day, the 14th day
Putting model group on the skin, (naive mice auris dextra only applies equivalent and puts acetone/olive oil matrix solution conduct pair on the skin at treatment group's mouse right ear
According to)；Wherein, treatment group started in the 7th day respectively with lactobacillus plantarum CCFM8610, Bb-12 and LGG (viable count is 1 ×
109CFU/mL stomach-filling) is carried out with 0.2mL bacterium solution// time dosage, (blank group and model group are not until modeling in the 14th day terminates
Bacterium solution intervention is carried out, only stomach-filling same amount of normal saline is as control)；All groupings are free water and ingest.
(i.e. the 0th day) measures the ear thickness of 5 groups of mouse using digital display spiral micrometer before modeling starts, after modeling
(i.e. the 15th day) takes blood and puts to death mouse, then measures mouse ear thickness, testing result such as Fig. 1 at once.
As shown in Figure 1, lactobacillus plantarum CCFM8610 and bifidobacterium bifidum Bb-12 treatment group significantly reduces after the test
The thickness (P < 0.05) of model group mouse ear, also, compared with Bb-12 group and LGG group, lactobacillus plantarum CCFM8610
It is bigger to the reduction degree of mouse ear thickness, it is stronger to the relief capabilities of mouse ear swelling degree.
By experimental result it is found that significantly alleviating mouse after lactobacillus plantarum CCFM8610 stomach-filling of the present invention treatment
The swelling degree and histopathology inflammation of ear, and it is more preferable than the remission effect of Bb-12 and LGG.
Embodiment 2: influence of the lactobacillus plantarum CCFM8610 to atopic dermatitis mouse skin inflammation
Weight is taken in the Healthy female C57BL/6 mouse 50 of 18-20g, is randomly divided into 5 groups, every group 10,5 groups of difference
Are as follows: blank group (Control), the model group that 2,4-dinitrofluorobenzene (2,4-dinitrofluorobenzene, DNFB) is administered
(Model), the CCFM8610 group that lactobacillus plantarum CCFM8610 is administered, is given at the Bb-12 group that animal bifidobacteria Bb-12 is administered
The LGG group of cascara buckthorn sugar Lactobacillus rhamnosus GG, wherein CCFM8610 group, Bb-12 group, LGG group are treatment group.
Experiment the totally two weeks: 1st day carries out depilation processing to 5 groups of back of mice skins, area be about 2.5cm ×
2.5cm, and model group is put in the DNFB solution painting for being 0.5% with 50 μ L concentration on the skin and treatment group's back of mice hair removal section carries out skin lesion cause
Quick and excitation is put model group on the skin with 20 μ L concentration for 0.2% DNFB solution painting and is treated for the 5th day, the 8th day, the 11st day, the 14th day
Group back of mice hair removal section (naive mice auris dextra only applies equivalent and puts acetone/olive oil matrix solution on the skin as control)；Wherein, it controls
Treatment group started respectively that (viable count is 1 × 10 with lactobacillus plantarum CCFM8610, Bb-12 and LGG in the 7th day9CFU/mL) with
0.2mL bacterium solution// time dosage carries out stomach-filling, until modeling in the 14th day terminates, (blank group and model group are dry without bacterium solution
In advance, only stomach-filling same amount of normal saline is used as control)；All groupings are free water and ingest.
(i.e. the 15th day) takes blood and puts to death mouse after modeling, and back of mice hair removal section skin is taken to carry out histopathology
Analysis carries out hematoxylin eosin staining by being sliced to back of mice histopathology of skin, then passes through vocational technology personnel
It carries out histopathology scoring (result such as Fig. 2).
As shown in Figure 2, naive mice skin of back epidermal cell structure is normal, and each layer of epidermis has no inflammatory reaction；It makes
Mould group back of mice skin lesion pathology are sexually revised in obvious inflammation hyperplasia, lymphocyte and plasmocyte infiltrating, while skin of back
Erosion, there are proliferations of fibrous tissue；There is fiber in lactobacillus plantarum CCFM8610 and the back of mice skin of Bb-12 treatment group
Hyperblastosis, epidermal hyperkeratosis and a small amount of inflammation；And the proliferation of fibrous tissue of LGG treatment group is obvious, epidermis is imperfect,
Speculate that skin has ulceration, incrustation, there are serious inflammatory reactions.
The above experiment shows that LGG group can not alleviate mouse skin pathological state, and lactobacillus plantarum CCFM8610 with
Bb-12 group is suitable to mouse skin pathological symptom remission effect, can significantly alleviate the ear swelling of atopic dermatitis model mouse
Degree improves the pathological characters of back of mice skin, to effectively alleviate the atopic dermatitis symptom of mouse.
Embodiment 3: influence of the lactobacillus plantarum CCFM8610 to atopic dermatitis patients SCORAD index
85 atopic dermatitis patients are recruited in this clinical test altogether, and all patients are randomly divided into 3 groups, and three groups are respectively
A group: the placebo (26 people) of maltodextrin, the oligosaccharide group (12 people) for taking prebiotic oligosaccharide are taken, takes plant cream
Treatment group's CCFM8610 group (47 people) of bacillus CCFM8610, wherein the product that placebo is taken is low not comprising prebiotics
Chitosan component is also free of the maltodextrin of probiotic ingredient；The product ingredient containing prebiotic oligosaccharides that oligosaccharide group is taken, but
Without probiotic ingredient；What CCFM8610 group was taken is containing lactobacillus plantarum CCFM8610 (viable count 1 × 109Cfu/ item),
The probiotics bacterial powder of appropriate oligosaccharide (1/3 inulin, 1/3 oligofructose, 1/3 galactooligosaccharide).
During the whole test process, lactobacillus plantarum CCFM8610's is probiotics bacterial powder to bacterium mode, can directly be taken
With or warm water (be no more than 37 DEG C) take after mixing it with water and take, dosage is 1/day.
Test probationary period 2 weeks the clinical test phase 8 weeks, amounts to 10 weeks.
Probationary period refers to the period of preparation before clinical test, contacts within 2 weeks patient in advance before the test, counts patient
Number informs that it tests property and content, signs informed consent form, while coordinating hospital and the time of doctor, and prepares examination
Test required material；The clinical test phase refer to made a definite diagnosis by doctor and voluntary participation test patient, taken after physical examination
Placebo, oligosaccharide or the time of probiotics continue 8 weeks.
After testing probationary period, the clinical test phase starts preceding first visit, answers after clinical test the 8th week all patients
It examines, the observation index such as record skin lesion area, the skin being grievously injured degree, itch degree and score value inquire compliance, record bad anti-
It answers, specific experiment process such as Fig. 3, experimental result such as Fig. 4, wherein T0 represents the time that clinical test starts, and T8 represents 8 weeks benefits
The time that raw bacterium Intervention trial is completed.
This clinical test uses the standardization severity index-SCORING Atopic Dermatitis index of AD
(SCORAD index) assesses the diagnosis to mild AD.
As shown in figure 4, final 8 patients are left out, totally 77 complete clinical research, and patient takes 8 weeks respectively
Probiotics bacterial powder, after placebo or oligosaccharide, lactobacillus plantarum CCFM8610 group patient its SCORAD index after assessment
It is remarkably decreased (P < 0.05) compared to before taking probiotics, apparent improve occurs in patient symptom.
Points for attention:
1, all patients are apprised of before the test and not eat during test the fermentation containing viable microbial and produce
Product.
2, it is arranged in period of pregnancy or nursing period with the patient of active anaphylaxis (respiratory tract or skin) disease or infectious disease
In addition in this research.
3, probiotics, antibiotic or immunomodulator treatment have been received within 3 months before recruitment time
Patient, or the patient for having received oral steroid therapy for one month before recruitment are also excluded from and study it at this
Outside.
4, all patients are both needed to signature informed consent form in registration.
Embodiment 4: the influence that lactobacillus plantarum CCFM8610 scores to atopic dermatitis patients DLQI
85 atopic dermatitis patients are recruited in this clinical test altogether, and all patients are randomly divided into 3 groups, and three groups are respectively
A group: the placebo (26 people) of maltodextrin, the oligosaccharide group (12 people) for taking prebiotic oligosaccharide are taken, takes plant cream
Treatment group's CCFM8610 group (47 people) of bacillus CCFM8610, wherein the product that placebo is taken is low not comprising prebiotics
Chitosan component is also free of the maltodextrin of probiotic ingredient；The product ingredient containing prebiotic oligosaccharides that oligosaccharide group is taken, but
Without probiotic ingredient；What CCFM8610 group was taken is containing lactobacillus plantarum CCFM8610 (viable count 1 × 109Cfu/ item),
The probiotics bacterial powder of appropriate oligosaccharide (1/3 inulin, 1/3 oligofructose, 1/3 galactooligosaccharide).
During the whole test process, lactobacillus plantarum CCFM8610's is probiotics bacterial powder to bacterium mode, can directly be taken
With or warm water (be no more than 37 DEG C) take after mixing it with water and take, dosage is 1/day.
Test probationary period 2 weeks the clinical test phase 8 weeks, amounts to 10 weeks.
Probationary period refers to the period of preparation before clinical test, contacts within 2 weeks patient in advance before the test, counts patient
Number informs that it tests property and content, signs informed consent form, while coordinating hospital and the time of doctor, and prepares examination
Test required material；The clinical test phase refer to made a definite diagnosis by doctor and voluntary participation test patient, taken after physical examination
Placebo, oligosaccharide or the time of probiotics continue 8 weeks.
All patients after testing probationary period, the clinical test phase start before, fill in after clinical test the 8th week
DLQI grade form influences size caused by patient's various aspects for assessing 7 days atopic dermatitis in the past.
This clinical test uses most common dermatology quality of life index (dermatology life
Quality index, DLQI) scale, patient's complete independently scale fills in, and it is right at the past 7 days that investigation content is related to skin disease
It is influenced caused by patient, including physiology, psychology, social activities, human communication, family, treatment etc., each topic uses 4 grades
Point-score, total score 30 are divided, and the score value the high, prompt skin disease bigger to patient effect, evaluation AD life in patients variation.
As shown in figure 5, patient is after placebo or oligosaccharide intervention in 8 weeks, DLQI's DLQI appraisal result scores
Without downward trend, on the various aspects of minimal invasive treatment almost without influence；And the patient by 8 weeks probiotics bacterial dried bean noodles after pre-,
Downward trend, with placebo compared with oligosaccharide group, lactobacillus plantarum CCFM8610 of the present invention is presented in its quality of life index
Group, there is significantly more decline in DLQI scoring, although not occurring the difference of conspicuousness in data statistics meaning, this
It may be intervention time deficiency, the influence to the physiology of patient, psychology, social activities, human communication and family etc. is not yet
Enough influences are generated, but have changed the quality of life of AD patient, so that the quality of life of patient is towards positive side
To development.
Embodiment 5: the preparation of the fermentation beverage made of fruits or vegetables containing lactobacillus plantarum CCFM8610
Specific step is as follows:
First by fresh vegetables, fruit clean after squeeze the juice, then by the juice squeezed at 140 DEG C of temperature high temperature thermal sterilization
About 37 DEG C of temperature are cooled to after 2 seconds immediately, then is inoculated with and plants according to the inoculum concentration of percent by volume 5% in juice after sterilization
Object lactobacillus CCFM8610, finally by the juice after inoculation in the 16h that ferments at 30 DEG C to get containing lactobacillus plantarum
The fermentation beverage made of fruits or vegetables of CCFM8610 viable bacteria.
Through detecting, the pH of this fermentation beverage made of fruits or vegetables for containing lactobacillus plantarum CCFM8610 viable bacteria is 3.6, and viable count is reachable
1.3×109cfu/mL。
By this contain lactobacillus plantarum CCFM8610 viable bacteria fermentation beverage made of fruits or vegetables continuous one week to atopic dermatitis patients
It takes, the affected part swelling of patient's dermatitis can be effectively relieved, also can effectively reduce patient SCORAD index and DLQI scoring, make patient's disease
There is apparent improve in shape and quality of life.
Embodiment 6: the preparation of the acidified milk containing lactobacillus plantarum CCFM8610
Specific step is as follows:
At first by raw milk (defatted milk, fresh milk, recovery milk etc.) through 95 DEG C, 20min or 140 DEG C, 2 seconds high-strength hots
It is cooled to 37 DEG C after reason, lactobacillus plantarum CCFM8610 is then inoculated into sterilizing according to the inoculum concentration of percent by volume 3~5%
Raw milk afterwards, then according to the inoculum concentration of percent by volume 3~5% in the raw milk for being vaccinated with lactobacillus plantarum CCFM8610
Inoculation can symbiosis the commercial fermentation agent lactobacillus bulgaricus for preparing Yoghourt or streptococcus thermophilus, finally by the raw material after inoculation
Cream in 37 DEG C of mixed fungus fermentations to titratable acidity be 0.6%~0.7% (in terms of lactic acid) to get to contain lactobacillus plantarum of the present invention
The acidified milk of CCFM8610 viable bacteria.
Through detecting, this titratable acidity for containing lactobacillus plantarum CCFM8610 viable bacteria fermentation cream has reached 75 ° of T, viable count
Reach 1.23 × 109CFU/mL。
Acidified milk continuous one week that this is contained lactobacillus plantarum CCFM8610 viable bacteria is taken to atopic dermatitis patients, can
The affected part swelling of patient's dermatitis is effectively relieved, also can effectively reduce patient SCORAD index and DLQI scoring, make patient symptom and life
There is apparent improve in bioplasm amount.
Although the present invention has been described by way of example and in terms of the preferred embodiments, it is not intended to limit the invention, any to be familiar with this skill
The people of art can do various change and modification, therefore protection model of the invention without departing from the spirit and scope of the present invention
Enclosing subject to the definition of the claims.
Claims (10)
1. application of the lactobacillus plantarum CCFM8610 in the product of preparation prevention and/or treatment atopic dermatitis.
2. lactobacillus plantarum CCFM8610 as described in claim 1 is in preparation prevention and/or the product for the treatment of atopic dermatitis
In application, which is characterized in that in the product, the viable count of lactobacillus plantarum CCFM8610 is not less than 1 × 106CFU/
mL。
3. lactobacillus plantarum CCFM8610 as claimed in claim 1 or 2 is in preparation prevention and/or the production for the treatment of atopic dermatitis
Application in product, which is characterized in that the product includes food, drug or health care product.
4. lactobacillus plantarum CCFM8610 as claimed in claim 3 is in preparation prevention and/or the product for the treatment of atopic dermatitis
In application, which is characterized in that the drug contains lactobacillus plantarum CCFM8610, pharmaceutical carrier and/or pharmaceutic adjuvant.
5. lactobacillus plantarum CCFM8610 as claimed in claim 3 is in preparation prevention and/or the product for the treatment of atopic dermatitis
In application, which is characterized in that the food includes to be produced using leavening containing lactobacillus plantarum CCFM8610
Dairy products, bean product or fruit and vegetable product；Or the food includes the solid beverage containing lactobacillus plantarum CCFM8610.
6. a kind of for preventing and/or treating the product of atopic dermatitis, which is characterized in that the product contains lactobacillus plantarum
CCFM8610。
7. as claimed in claim 6 a kind of for preventing and/or treating the product of atopic dermatitis, which is characterized in that described
In product, the viable count of lactobacillus plantarum CCFM8610 is not less than 1 × 106CFU/mL。
8. as claimed in claims 6 or 7 a kind of for preventing and/or treating the product of atopic dermatitis, which is characterized in that institute
Stating product includes food, drug or health care product.
9. as claimed in claim 8 a kind of for preventing and/or treating the product of atopic dermatitis, which is characterized in that described
Drug contains lactobacillus plantarum CCFM8610, pharmaceutical carrier and/or pharmaceutic adjuvant.
10. a kind of product for atopic dermatitis as claimed in claim 8, which is characterized in that the food includes to use
Dairy products, bean product or the fruit and vegetable product that leavening containing lactobacillus plantarum CCFM8610 produces；Or the food packet
Containing the solid beverage containing lactobacillus plantarum CCFM8610.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811404822.0A CN109498660A (en) | 2018-11-23 | 2018-11-23 | A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811404822.0A CN109498660A (en) | 2018-11-23 | 2018-11-23 | A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109498660A true CN109498660A (en) | 2019-03-22 |
Family
ID=65750023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811404822.0A Pending CN109498660A (en) | 2018-11-23 | 2018-11-23 | A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109498660A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110616167A (en) * | 2019-08-22 | 2019-12-27 | 江南大学 | Bifidobacterium capable of relieving atopic dermatitis and application thereof |
| CN111955740A (en) * | 2020-08-12 | 2020-11-20 | 量子高科(中国)生物股份有限公司 | Composition for relieving and treating atopic dermatitis and application thereof |
| WO2021138599A1 (en) * | 2020-01-03 | 2021-07-08 | Forte Subsidiary, Inc. | Cosmetic compositions |
| CN116042426A (en) * | 2021-10-28 | 2023-05-02 | 南京盛德生物科技研究院有限公司 | Lactobacillus plantarum WSH048, screening method thereof and preparation method of fermentation product thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102827796A (en) * | 2012-09-03 | 2012-12-19 | 江南大学 | Lactobacillus plantarum with cadmium removing function and usage thereof |
| CN106573023A (en) * | 2014-08-13 | 2017-04-19 | 雀巢产品技术援助有限公司 | Lactobacillus plantarum CNCM I-4026 preparations and skin health |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
| WO2018143678A1 (en) * | 2017-01-31 | 2018-08-09 | 경희대학교 산학협력단 | Novel lactic acid bacteria and use thereof |
-
2018
- 2018-11-23 CN CN201811404822.0A patent/CN109498660A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102827796A (en) * | 2012-09-03 | 2012-12-19 | 江南大学 | Lactobacillus plantarum with cadmium removing function and usage thereof |
| CN106573023A (en) * | 2014-08-13 | 2017-04-19 | 雀巢产品技术援助有限公司 | Lactobacillus plantarum CNCM I-4026 preparations and skin health |
| WO2018143678A1 (en) * | 2017-01-31 | 2018-08-09 | 경희대학교 산학협력단 | Novel lactic acid bacteria and use thereof |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110616167A (en) * | 2019-08-22 | 2019-12-27 | 江南大学 | Bifidobacterium capable of relieving atopic dermatitis and application thereof |
| CN110616167B (en) * | 2019-08-22 | 2022-02-01 | 江南大学 | Bifidobacterium capable of relieving atopic dermatitis and application thereof |
| WO2021138599A1 (en) * | 2020-01-03 | 2021-07-08 | Forte Subsidiary, Inc. | Cosmetic compositions |
| CN111955740A (en) * | 2020-08-12 | 2020-11-20 | 量子高科(中国)生物股份有限公司 | Composition for relieving and treating atopic dermatitis and application thereof |
| CN116042426A (en) * | 2021-10-28 | 2023-05-02 | 南京盛德生物科技研究院有限公司 | Lactobacillus plantarum WSH048, screening method thereof and preparation method of fermentation product thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN109498660A (en) | A kind of application for the lactobacillus plantarum CCFM8610 that can alleviate atopic dermatitis | |
| TWI463986B (en) | New use of lactobacillus plantarum cmu995 strain | |
| US20230048705A1 (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
| CN106794202A (en) | Improve the composition and method of human health and nutrition | |
| EA031426B1 (en) | Use of bifidobacterium lactis bl-04 for treatment of respiratory tract illnesses | |
| CN102791849A (en) | Lactic acid bacterium-containing preparation | |
| CN111329884B (en) | Application of lactobacillus plantarum BC299 in medicines and foods for treating inflammatory bowel diseases and psychogenic problems | |
| CN109380733A (en) | A kind of probiotics powder agent and preparation method thereof | |
| RU2725883C2 (en) | Composition for reducing intestinal gas production | |
| CN110917174A (en) | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof | |
| Yoshida et al. | Clinical effects of probiotic Bifidobacterium breve supplementation in adult patients with atopic dermatitis | |
| CN116987608A (en) | Probiotic composition and application thereof in preparation of depression-complicated diarrhea-type irritable bowel syndrome medicines | |
| Manzano et al. | Safety and tolerance of three probiotic strains in healthy infants: A multi-centre randomized, double-blind, placebo-controlled trial | |
| CN116077415B (en) | Ternary probiotic factor composition for regulating skin microecological balance | |
| EP1838158B1 (en) | Use of a fermented milk containing l. casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction | |
| KR102214820B1 (en) | Composition for improving of skin conditions | |
| US20220265545A1 (en) | Composition for improving skin condition | |
| JP6261688B2 (en) | QOL improvement or persistence agent | |
| KR20200058849A (en) | Composition for reduction or treatment of atopic symptom comprising high immune active Lactobacillus sakei probio-65 ghost cell or Lactobacillus sakei probio-65 extract | |
| CN115518080A (en) | Application of bifidobacterium lactis BLA80 in improving and relieving anaphylactic reaction | |
| US20210315808A1 (en) | Bacillus subtilis containing composition for teatement of gastrointestinal irregulairty | |
| CN116919879B (en) | Biological probiotics composition with skin microecology regulating effect and preparation method and application thereof | |
| US20190125810A1 (en) | Bacillus subtilis containing composition for teatement of gastrointestinal irregulairty | |
| JP7130220B2 (en) | skin moisturizer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |